checkAd

     145  0 Kommentare Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 - Seite 2

    BioVaxys quickly followed up the acquisition by announcing the allowance of DPX's formulation patents in both the United States, and Japan, with patents currently pending in the EU. BioVaxys has additionally announced it has entered the national phase also in Canada and Australia with its patent application for DPX-survivin/MAGE A9 ("DPX SurMAGE"), a DPX formulation of the tumor-associated antigens survivin and MAGE A9 as a dual targeted immunotherapy.

    DPX is a proprietary lipid-based delivery platform with no aqueous component that can be formulated with a range of packaged antigens, proteins, peptides, mRNA, or small molecules.  Its unique "no release" mechanism of action allows antigen presenting cells (APCs) to be attracted to the injection site, facilitating a robust and sustained immune response.

    For reference, the smallest dose of a currently approved vaccine is 0.1ml for Sanofi-Pasteur's Fluzone Intradermal Quadrivalent vaccine. Low dose volume delivery of DPX formulated B-cell epitope is designed to be delivered in single dose as low as 50µL to 90 µL.

    "Expanding patent protection into major biopharma markets… further increases the value of the DPX platform for our Company," said Kovan. "Having an ability to create low dose DPX+B cell epitope formulations is an attractive approach for packaging antigens for cancer immunotherapeutics  and therapeutic vaccines such as for influenza, Zika virus, RSV, HSV, and many other viral or bacterial pathogens.

    Since receiving its first greenlight from governments in North America, Europe, and other parts of the world, Moderna, Inc. (NASDAQ: MRNA) continues to work diligently in developing new treatments based on its mRNA therapeutics options. Recently in late April, a new "personalised" mRNA vaccine against the deadliest form of skin cancer (melanoma) was given to its first patients in its ongoing final-stage Phase III trials.

    According to midstage trial data released in December 2023, Moderna experimental cancer vaccine, when used in combination with partners Merck's Keytruda, reduced the risk of death or relapse in patients. The joint Moderna/Merck efforts are also testing the vaccine with Keytruda against other tumor types, including non-small cell lung cancer.

    "The melanoma curve is flattening, people are not dying anymore," said Stephane Bancel, CEO of Moderna, in an interview with CNBC. "We believe that the earlier you go in disease, the stronger the immune system of a patient is, meaning our individualized treatment should work even better."

    Seite 2 von 5



    PR Newswire (engl.)
    0 Follower
    Autor folgen

    Verfasst von PR Newswire (engl.)
    Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 - Seite 2 USA News Group Commentary Issued on behalf of BioVaxys Technology Corp. VANCOUVER, BC, May 1, 2024 /PRNewswire/ - USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being …